Nurix Therapeutics, Inc.
NRIXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of. With a market capitalization of $2.71B, it sits in mid-cap territory. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Market Cap
$2.71B
Beta
1.80
P/E (TTM)
—
P/E (Fwd)
-24.54
EPS (TTM)
$-3.46
EPS (Fwd)
$-1.07
ROE
-80.3%
ROA
-40.1%
Cash
$443.5M
Total Debt
$58.1M
Free CF
-$164.6M
52W Change
169.5%
Annual Financials
Cash vs Debt
Where NRIX stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, NRIX finished 42.23% above its 150-day moving average ($18.78) and 44.93% above its 200-day moving average ($18.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NRIX overbought or oversold?
At the August 27, 2026 close, NRIX's RSI(14) was 62.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $443.5M in cash and $58.1M in debt, NRIX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$164.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -80.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $38.6M (2022) to $84.0M (2025), reflecting a 117% increase over the period.
Nurix Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Nurix Therapeutics, Inc. and its sector.